2023
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S, Moutier C, Rush A, Johnson G, Tal I, Chen P, Davis L, Hicks P, Wilcox J, Planeta B, Lauro K, Scrymgeour A, Kasckow J, Mohamed S. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine 2023, 54: 1172-1183. PMID: 37859623, DOI: 10.1017/s0033291723003008.Peer-Reviewed Original ResearchMajor depressive disorderNext-step treatmentsLifetime suicidal ideationSuicidal ideationSuicide riskLower positive mental healthPrevalence of SISevere depressive episodeAcute treatment periodCurrent MDD episodeBaseline suicidal ideationMore childhood adversitiesSuicide prevention interventionsRisk of SICurrent suicidal ideationAntidepressant treatmentMost patientsInitial medicationMDD episodeMedication treatmentDepressive episodeDepressive disorderTreatment periodDepression trialsPrevention interventions
2022
Childhood adversity and adulthood major depressive disorder
Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022, 76: 36-44. PMID: 35366613, DOI: 10.1016/j.genhosppsych.2022.03.008.Peer-Reviewed Original ResearchConceptsMajor depressive disorderChildhood adversityDepressive disorderSuicidal ideationLower remission rateLower depression severityDepression Outcomes studyMore lifetime episodesGOV IDENTIFIERRemission rateClinical featuresClinical outcomesSevere depressionTreatment strategiesLifetime episodesOutcome studiesDepression severitySwitching treatmentYounger ageSecondary analysisComorbid PTSDChildhood maltreatmentWorse qualitySpecific typesDisorders
2016
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideation
2010
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, Mohamed S, Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. The Journal Of Clinical Psychiatry 2010, 71: 915-22. PMID: 20361918, DOI: 10.4088/jcp.09m05699gre.Peer-Reviewed Original ResearchConceptsBaseline suicidal ideationHamilton Depression Rating ScaleDepression Rating ScaleSubthreshold depressive symptomsCalgary Depression Rating ScaleDepressive symptomsSuicidal ideationSchizoaffective disorderClinical Global Impressions-SeverityBeck Hopelessness ScaleDSM-IV-diagnosed schizophreniaRating ScaleTreatment-emergent suicidal ideationPlacebo-controlled trialSuicidal ideation measuresItem 3Citalopram augmentationFinal visitPlacebo augmentationSecondary outcomesPrimary outcomeOlder outpatientsInterSePT ScaleCitalopramPlacebo